Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma
- PMID: 24606022
- DOI: 10.1513/AnnalsATS.201310-354OC
Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma
Abstract
Rationale: Measurement of sputum or blood eosinophils may allow identification of a severe eosinophilic asthma population responsive to mepolizumab.
Objectives: The primary objective was assessment of a single blood eosinophil measurement to predict future eosinophil measurements in the following year versus using multiple blood eosinophil measurements. In addition, we examined whether a single sputum or blood eosinophil measurement was a useful biomarker for predicting treatment response to mepolizumab.
Methods: Based on data from placebo subjects (n = 155), we determined whether a blood eosinophil count of 150/μl or greater at screening remained on average above this level during the following year. The rate of exacerbation reduction in the sputum substudy population based on the screening blood eosinophil count and sputum eosinophils was evaluated.
Measurements and main results: Of 115 patients with eosinophils 150/μl or greater at screening, 98 (85%) remained above this level in their post-screening average. Using the average of two, three or four measurements 150/μl or greater, 97 (85%), 103 (90%), and 105 (92%) have postscreening averages above 150/μl. Mepolizumab reduced exacerbations by 69% (95% confidence interval [CI] = 41-83%) in subjects with baseline sputum eosinophils of 3% or greater compared with 66% (95% CI = 7-87%) in subjects with baseline sputum eosinophils under 3%. The reduction was 72% (95% CI = 41-83%) in subjects with blood eosinophils of 150/μl or greater compared with 30% (95% CI = -134 to 79%) in subjects with blood eosinophils under 150/μl.
Conclusions: A single measurement of 150/μl or greater predicted the average of subsequent measurements being 150/μl or greater in 85% of this population. Using an average of multiple measurements only marginally increases the sensitivity. Sputum eosinophils did not predict treatment response with mepolizumab.
Similar articles
-
Biomarkers for severe eosinophilic asthma.J Allergy Clin Immunol. 2017 Dec;140(6):1509-1518. doi: 10.1016/j.jaci.2017.10.005. J Allergy Clin Immunol. 2017. PMID: 29221581 Review.
-
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.Am J Respir Crit Care Med. 2018 Jan 1;197(1):38-46. doi: 10.1164/rccm.201707-1323OC. Am J Respir Crit Care Med. 2018. PMID: 28915080 Clinical Trial.
-
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.Lancet Respir Med. 2016 Jul;4(7):549-556. doi: 10.1016/S2213-2600(16)30031-5. Epub 2016 May 10. Lancet Respir Med. 2016. PMID: 27177493 Clinical Trial.
-
Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.Clin Exp Allergy. 2016 Jun;46(6):793-802. doi: 10.1111/cea.12695. Clin Exp Allergy. 2016. PMID: 26685004
-
Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.Ther Adv Respir Dis. 2015 Aug;9(4):135-45. doi: 10.1177/1753465815581279. Epub 2015 Apr 21. Ther Adv Respir Dis. 2015. PMID: 25900924 Review.
Cited by
-
Eosinophilic Patterns in Patients with Seasonal Allergy Affected by Bronchial Asthma and Rhinitis/Rhinosinusitis: Efficacy of Benralizumab in Patients with the Persistent Pattern.J Clin Med. 2024 Jan 28;13(3):754. doi: 10.3390/jcm13030754. J Clin Med. 2024. PMID: 38337448 Free PMC article.
-
Relationship between serum iron and blood eosinophil counts in asthmatic adults: data from NHANES 2011-2018.Front Immunol. 2023 Sep 4;14:1201160. doi: 10.3389/fimmu.2023.1201160. eCollection 2023. Front Immunol. 2023. PMID: 37731511 Free PMC article.
-
Exposure to violence and asthma in Puerto Rican youth with high Th2 immunity.Pediatr Pulmonol. 2023 Aug;58(8):2289-2297. doi: 10.1002/ppul.26483. Epub 2023 May 16. Pediatr Pulmonol. 2023. PMID: 37191387 Free PMC article.
-
Delineating asthma according to inflammation phenotypes with a focus on paucigranulocytic asthma.Chin Med J (Engl). 2023 Jul 5;136(13):1513-1522. doi: 10.1097/CM9.0000000000002456. Chin Med J (Engl). 2023. PMID: 37185590 Free PMC article. Review.
-
Upper airway disease diagnosis as a predictive biomarker of therapeutic response to biologics in severe asthma.Front Med (Lausanne). 2023 Mar 22;10:1129300. doi: 10.3389/fmed.2023.1129300. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37035303 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical